Skip to main content
. 2016 Jul 12;9:65–77. doi: 10.2147/PGPM.S62918

Figure 1.

Figure 1

Summary of somatic cancer biomarkers and targeted therapies.

Notes: This figure depicts examples of key signaling pathways and downstream effects of mutations within somatic biomarkers, and their respective targeted therapies.

Abbreviations: ALK, anaplastic lymphoma kinase; JAK, Janus kinase; mTOR, mammalian target of rapamycin; p13K, phosphoinositide 3-kinase; TDM-l, ado-trastuzumab emtansine; VEGFR, vascular endothelial growth factor receptor.